News

Filter

76 to 85 of 96315 results

Generics maker IGI Laboratories acquires 18 AstraZeneca drugs

Generics maker IGI Laboratories acquires 18 AstraZeneca drugs

25-09-2014

New Jersey-based specialty generic company IGI Laboratories has acquired regulatory rights, related documents…

AstraZenecaGenericsIGI LaboratoriesLicensingUSA

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

NicOx and Valeant's glaucoma candidate Vesneo meets Ph III endpoint

25-09-2014

Canada’s Valeant Pharmaceuticals International and France’s NicOx have reported positive top-line…

Bausch & LombCanadaFinancialFranceNicOxOphthalmicsPharmaceuticalResearchValeant Pharmaceuticals InternationalVesneo

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

25-09-2014

Switzerland-based Celgene International, a wholly-owned subsidiary of US biotech major Celgene, say that…

AbraxaneBiotechnologyCelgene Corp.OncologyRegulationSwitzerland

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

25-09-2014

French pharma major Sanofi subsidiary Genzyme has entered into a research collaboration with the USA’s…

BiotechnologyFranceGenzymeOphthalmicsRare diseasesSanofi

GlaxoSmithKline’s $490 million fine to spark pharma strategy shift in emerging markets, says analyst

GlaxoSmithKline’s $490 million fine to spark pharma strategy shift in emerging markets, says analyst

25-09-2014

UK pharma giant GlaxoSmithKline’s involvement in a large-scale bribery scandal in China came to an…

BrazilChinaGlaxoSmithKlineIndiaManagementMarkets & MarketingPharmaceutical

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

FDA warning letters rise 78% over six years with increase expected in 2015

FDA warning letters rise 78% over six years with increase expected in 2015

25-09-2014

The number of warning letters sent by the US Food and Drug Administration increased substantially by…

PharmaceuticalRegulationUSA

Medicines Australia says PBS is costing less than expected

Medicines Australia says PBS is costing less than expected

25-09-2014

Trade group Medicines Australia says the release of the 2013-14 Final Budget Outcome shows the government…

AustraliaEntertainment CultureFinancialHealthcare in AustraliaPharmaceuticalPharmaceutical Benefits SchemePharmaceuticals policy

76 to 85 of 96315 results

Back to top